Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Net Sales in Rest of World: $1,000M in FY2025, down 3.4% from a year earlier.
Latest, FY2025
1,000
Period ended Dec 31, 2025
Change on a year earlier
-3.4%
1,035 in FY2024
History
8 years
Since FY2018
Sources
8
Documents cited below
Where the FY2025 figure comes from
“|| Promacta/Revolade | Oncology | Immune thrombocytopenia (ITP), severe aplastic anemia (SAA) | 636 | -46 | 1 000 | -3 | -4 | 1 636 | -26 | -27”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F (Top 20 Brands US / Rest of World).
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Net Sales in Rest of World ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,000 | -3.4% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 1,035 | -2.7% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2023 | Dec 31, 2023 | 1,064 | +5.9% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,005 | -6.0% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2021 | Dec 31, 2021 | 1,069 | +18.1% | Novartis Form 6-K (0001370368-22-000009) ↗ |
| FY2020 | Dec 31, 2020 | 905 | +24.8% | Novartis Form 6-K (0001370368-21-000008) ↗ |
| FY2019 | Dec 31, 2019 | 725 | +22.3% | Novartis Form 6-K (0001370368-20-000007) ↗ |
| FY2018 | Dec 31, 2018 | 593 | – | Novartis Form 6-K (0001370368-19-000006) ↗ |
Breakdown
What makes up net Sales in Rest of World
Cite this data
StockData. (2026). Novartis Net Sales in Rest of World ($M), annual FY2018–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-promacta-revolade-row-sales
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.